Literature DB >> 22343231

Surgical management of epithelial ovarian cancer.

Ritu Salani1, Robert E Bristow.   

Abstract

Ovarian cancer affects approximately 21,880 women and accounts for over 13,000 deaths annually in the United States. Although survival rates have improved over the past several decades, directly as a result of advances in chemotherapy and surgery, ovarian cancer continues to have high mortality rates. Understanding the multiple roles of surgery throughout the disease course is the focus of this review.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22343231     DOI: 10.1097/GRF.0b013e31824b4629

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  14 in total

1.  Effects of let-7c on the proliferation of ovarian carcinoma cells by targeted regulation of CDC25a gene expression.

Authors:  Wei Zhang; Qingru Zeng; Zhenying Ban; Jing Cao; Tianjiao Chu; Dongmei Lei; Chi Liu; Wentao Guo; Xianxu Zeng
Journal:  Oncol Lett       Date:  2018-08-20       Impact factor: 2.967

Review 2.  Selecting the best strategy of treatment in newly diagnosed advanced-stage ovarian cancer patients.

Authors:  Lucas Minig; Cristina Zorrero; Pablo Padilla Iserte; Andres Poveda
Journal:  World J Methodol       Date:  2015-12-26

3.  miR-26a inhibits the proliferation of ovarian cancer cells via regulating CDC6 expression.

Authors:  Ting-Yi Sun; Hong-Jian Xie; Hui He; Zhen Li; Ling-Fei Kong
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

4.  Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC.

Authors:  Álvaro Jesús Gómez-Ruiz; Alida González-Gil; José Gil; Álvaro Navarro-Barrios; Felipe Alconchel; Elena Gil; Jerónimo Martínez; Aníbal Nieto; Francisco Barceló; Pedro Antonio Cascales-Campos
Journal:  Clin Exp Metastasis       Date:  2019-07-03       Impact factor: 5.150

5.  Diagnostic impact of ascites cytology in 941 patients: malignancy rates and time of detection in ovarian cancer relative to other tumor types.

Authors:  Jens Krugmann; Corinna Lang Schwarz; Balint Melcher; William Sterlacci; Michael Vieth; Sophia Rösch; Johannes Lermann
Journal:  Arch Gynecol Obstet       Date:  2020-04-28       Impact factor: 2.344

6.  A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients.

Authors:  Meiying Zhang; Yifeng He; Xiangjun Sun; Qing Li; Wenjing Wang; Aimin Zhao; Wen Di
Journal:  J Ovarian Res       Date:  2014-02-08       Impact factor: 4.234

7.  A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology.

Authors:  Ming Chen; Ying Jin; Yalan Bi; Jie Yin; Yongxue Wang; Lingya Pan
Journal:  Onco Targets Ther       Date:  2014-10-16       Impact factor: 4.147

8.  c-Fos mediates α1, 2-fucosyltransferase 1 and Lewis y expression in response to TGF-β1 in ovarian cancer.

Authors:  Yingying Hao; Liancheng Zhu; Limei Yan; Juanjuan Liu; Dawo Liu; Na Gao; Mingzi Tan; Song Gao; Bei Lin
Journal:  Oncol Rep       Date:  2017-10-23       Impact factor: 3.906

Review 9.  Transvaginal ultrasonography in ovarian cancer screening: current perspectives.

Authors:  John R van Nagell; John T Hoff
Journal:  Int J Womens Health       Date:  2013-12-20

10.  The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer.

Authors:  Erik Škof; Sebastjan Merlo; Gasper Pilko; Borut Kobal
Journal:  Radiol Oncol       Date:  2016-07-19       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.